# Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung Cancer

> **NCT07226999** · PHASE2,PHASE3 · RECRUITING · sponsor: **Pfizer** · enrollment: 550 (estimated)

## Conditions studied

- Small Cell Lung Cancer (SCLC)

## Interventions

- **DRUG:** PF-08634404
- **BIOLOGICAL:** Atezolizumab
- **DRUG:** Chemotherapy

## Key facts

- **NCT ID:** NCT07226999
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-09
- **Primary completion:** 2030-06-14
- **Final completion:** 2034-03-11
- **Target enrollment:** 550 (ESTIMATED)
- **Last updated:** 2026-04-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07226999

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07226999, "Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07226999. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*